The Role of Complement in Liver Cancer

Abstract

This project explores the role of the complement cascade in the development of hepatocellular carcinoma (HCC). HCC is the second leading cause of cancer-related deaths worldwide, and the incidence may be up to five times higher among U.S. veterans than in the general population.Chronic inflammatory diseases of the liver, such as hepatitis and nonalcoholic steatohepatitis (NASH), are strongly associated with an increased risk of HCC, and a large body of literature shows that the complement system is activated in these diseases (1-5). The association of inflammatory liver diseases with HCC suggests that prolonged inflammation directly contributes to tumor formation. The underlying mechanisms of this are incompletely understood, however, limiting our ability to prevent HCC in at-risk patients. Based on our recent work, we believe that complement inhibitory drugs may be effective for reducing liver inflammation and preventing and/or treating HCC.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2023
Accession Number
AD1216888

Entities

People

  • Joshua Thurman

Organizations

  • University of Colorado Boulder

Tags

DTIC Thesaurus Topics

  • Animals
  • Biomedical Research
  • Bone Marrow
  • Cells
  • Colorado
  • Department Of Defense
  • Diseases
  • Electronic Mail
  • Hepatitis
  • Inflammation
  • Inhibition
  • Literature
  • Liver Diseases
  • Lymphocytes
  • Medical Personnel
  • Myeloid Cells
  • Standards

Fields of Study

  • Medicine

Readers

  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.
  • Molecular and Cellular Biology
  • Oncology